|
Written by Staff and Wire Reports
|
|
Wednesday, 16 May 2012 19:05 |
Below is a look at some of the headlines for companies that made news in the healthcare sector on May 16, 2012.
|
|
Read more...
|
|
Written by George S. Mack of The Life Sciences Report
|
|
Wednesday, 16 May 2012 06:02 |
Newly discovered biomarkers could provide physicians with information that will aid in the diagnosis and treatment of disease. The big question for investors is whether, in light of the recent Supreme Court ruling Mayo Collaborative Services Inc. v. Prometheus Laboratories, companies will be able to profit from that innovation.
|
|
Read more...
|
|
Written by Staff and Wire Reports
|
|
Tuesday, 15 May 2012 18:52 |
Below is a look at some of the headlines for companies that made news in the healthcare sector on May 15, 2012.
|
|
Read more...
|
|
Written by M.E.Garza
|
|
Tuesday, 15 May 2012 06:26 |
Goldman Sachs upgrades Incyte (NASDAQ: INCY) from Neutral to Buy with a price target of $29 (up from $21), suggesting a 26% premium from today's prices as the drug discovery company focused on developing proprietary small molecule drugs becomes the latest M&A target.
|
|
Read more...
|
|
Written by Staff and Wire Reports
|
|
Monday, 14 May 2012 19:59 |
Below is a look at some of the headlines for companies that made news in the healthcare sector on May 14, 2012.
|
|
Read more...
|
|
Written by M.E.Garza
|
|
Monday, 14 May 2012 03:16 |
In an exclusive interview with Liz Cermak, Executive Vice President and Chief Commercial Officer of POZN, we discuss the implications of a European licensing deal for their migrane drug MT 400.
|
|
Read more...
|
|
Written by Staff and Wire Reports
|
|
Saturday, 12 May 2012 00:51 |
Below is a look at some of the headlines for companies that made news in the healthcare sector on May 11, 2012.
|
|
Read more...
|
|
Written by Staff and Wire Reports
|
|
Thursday, 10 May 2012 18:26 |
Below is a look at some of the headlines for companies that made news in the healthcare sector on May 10, 2012.
|
|
Read more...
|
|
Written by Brian Wilson, Contributor
|
|
Thursday, 10 May 2012 04:22 |
It's time to start tracking Lpath (LPTN) again. The San Diego-based pharmaceutical company is leading a new trend of lipid-based therapies and shares are once again on the rise as speculators begin to watch their drug portfolio and rumors of a takeover by pharmaceutical giant Pfizer (PFE) begin to re-surface.
|
|
Read more...
|
|
Written by Staff and Wire Reports
|
|
Wednesday, 09 May 2012 18:26 |
Below is a look at some of the headlines for companies that made news in the healthcare sector on May 9, 2012.
|
|
Read more...
|